

DAFTAR PUSTAKA

1. International League of Associations for Rheumatology. *International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis : Second Revision*, Edmonton, 2001 revised. *J Rheumatol*. 2001;31(2):390–2.
2. Palmer J, Shoop-Worrall S, Hyrich K, McDonagh JE. Update on the epidemiology, risk factors and disease outcomes of Juvenile idiopathic arthritis. *Best Pract Res Clin Rheumatol*. 2018;32(2):206–22.
3. Consolaro A, Lanni S, Schiappapietra B, Giancane G, Ravelli A, Davi S. Juvenile Idiopathic Arthritis: Diagnosis and Treatment. *Rheumatol Ther*. 2016;3(2):187–207.
4. Ghrahani R, Setiabudiawan B, Sapartini G, Puspasari H. Distribusi Subtipe Juvenile Idiopathic Arthritis di Bandung Distribution of Juvenile Idiopathic Arthritis Subtypes in Bandung. *Maj Kedokt Bandung*. 2012;44(2):101–5.
5. Giancane G, Alongi A, Ravelli A. Update on the pathogenesis and treatment of juvenile idiopathic arthritis. *Curr Opin Rheumatol*. 2017;29(5):523–9.
6. Crayne CB, Beukelman T. Juvenile Idiopathic Arthritis: Oligoarthritis and Polyarthritis. Vol. 65, *Pediatric Clinics of North America*. 2018. p. 657–74.
7. Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: A systematic review. *Jt Bone Spine*. 2014;81(2):112–7.
8. Ringold S, Weiss PF, Colbert RA, Dewitt EM, Lee T, Onel K, et al. Childhood arthritis and rheumatology research alliance consensus treatment plans for new-onset polyarticular Juvenile idiopathic arthritis. *Arthritis Care Res*. 2014;66(7):1063–72.
9. Rigante D, Bosco A, Esposito S. The Etiology of Juvenile Idiopathic Arthritis. *Clin Rev Allergy Immunol*. 2015;49(2):253–61.
10. Putt ME, Horton DB, Lewis JD, Strom BL, Rose CD, Scott FI, et al. Antibiotic Exposure and Juvenile Idiopathic Arthritis: A Case-Control Study. *Pediatrics*. 2015;136(2):e333–43.
11. Arvonen M, Virta LJ, Pokka T, Kröger L, Vähäsalo P. Repeated exposure to antibiotics in infancy: A predisposing factor for juvenile idiopathic arthritis or a sign of this group's greater susceptibility to infections? *J Rheumatol*. 2015;42(3):521–6.
12. Carlsen C, Jacobsson L, Brandt L, Cnattingius S, Stephansson O, Askling J. Perinatal characteristics, early life infections and later risk of rheumatoid arthritis and juvenile idiopathic arthritis. *Ann Rheum Dis*. 2009;68(7):1159–64.
13. Miller J1, Ponsonby AL2, Pezic A1, Kemp A1, Piper SE3, Akikusa JD4, Allen RC4, Munro JE4 EJ. Sibling Exposure and Risk of Juvenile Idiopathic Arthritis. *Arthritis Rheumatol*. 2015;1951–8.
14. Ellis JA, Ponsonby AL, Pezic A et al. CLARITY - ChiLdhood Arthritis Risk factor Identification sTudY. *Pediatr Rheumatol*. 2012;10:37.
15. Sheno S, Shaffer ML, Wallace CA. Environmental Risk Factors and Early-Life Exposures in Juvenile Idiopathic Arthritis: A Case-Control Study. *Arthritis Care Res*. 2016;68(8):1186–94.
16. Gardner-Medwin J, Baildam E, Davidson JE, Foster H, Chieng A, Wedderburn LR, et al. Influence of past breast feeding on pattern and severity of presentation of juvenile idiopathic arthritis. *Arch Dis Child*. 2015;101(4):348–51.
17. Hahn YS, Kim JG. Pathogenesis and clinical manifestations of juvenile rheumatoid arthritis. *Korean J Pediatr*. 2010;53(11):921–30.
18. Sen ES, Ramanan A V. Juvenile idiopathic arthritis-associated uveitis. *Best Pract Res Clin Rheumatol*. 2017;31(4):517–34.
19. Mori M, Nozawa T, Okura Y, Umebayashi H, Shimizu M, Kunishima T, et al. Clinical practice guidance for juvenile idiopathic arthritis (JIA) 2018. *Mod Rheumatol*. 2018;29(1):41–59.
20. Gilman AG. Goodman & Gilman's The Pharmacological Basis of Therapeutics Thirteenth Edition. Vol. 53, Mc Graw Hill Education. 2018. 1689-1699 p.
21. Data Sheet - Medsafe - Kenacort. 2020.
22. Medscape. Triamcinolone acetonide injectable suspension (Rx). 2020.

23. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Vol. 9, Allergy, Asthma and Clinical Immunology. 2013.
24. Ferrara G, Mastrangelo G, Barone P, La Torre F, Martino S, Pappagallo G, et al. Methotrexate in juvenile idiopathic arthritis: Advice and recommendations from the MARAJIA expert consensus meeting. Vol. 16, Pediatric Rheumatology. 2018.
25. Shann F. Drug Dose. 17th ed. Shann F, editor. Victoria, Australia: JR Medical Books; 2017.
26. Field MS, Stover PJ. Safety of folic acid. *Ann N Y Acad Sci*. 2018;1414(1):59–71.
27. Finch SL, Rosenberg AM, Vatanparast H. Vitamin D and juvenile idiopathic arthritis. Vol. 16, Pediatric Rheumatology. 2018.
28. Von Scheven E, Burnham JM. Vitamin D supplementation in the pediatric rheumatology clinic. *Curr Rheumatol Rep*. 2011;13(2):110–6.
29. Gröber U, Spitz J, Reichrath J, Kisters K, Holick MF. Vitamin D: Update 2013 - From rickets prophylaxis to general preventive healthcare. Vol. 5, Dermato-Endocrinology. 2013. p. 331–47.
30. Ross AC, Taylor CL, Yaktine AL, Del Valle HB. Dietary reference intakes for calcium and vitamin D/Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Food and Nutrition Board. Vol. 32, Endocrinology and Metabolism Clinics of North America. 2011. 181-194 p.
31. Marcinowska-Suchowierska E, Kupisz-Urbanska M, Lukaszkiwicz J, Pludowski P, Jones G. Vitamin D Toxicity a clinical perspective. Vol. 9, Frontiers in Endocrinology. 2018.
32. Ronner P. Netter's essential biochemistry. Elsevier, Inc. 2018;1–482.
33. Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M. Vitamin D deficiency in children and its management: Review of current knowledge and recommendations. Vol. 122, Pediatrics. 2008. p. 398–417.
34. Menon V, Kar S, Suthar N, Nebhinani N. Vitamin D and depression: A critical appraisal of the evidence and future directions. Vol. 42, Indian Journal of Psychological Medicine. 2020. p. 11–21.
35. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: Modulator of the immune system. Vol. 10, Current Opinion in Pharmacology. 2010. p. 482–96.
36. Cutolo M, Pizzorni C, Sulli A. Vitamin D endocrine system involvement in autoimmune rheumatic diseases. Vol. 11, Autoimmunity Reviews. 2011. p. 84–7.
37. Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: Metabolism, molecular mechanism of action, and pleiotropic effects. *Physiol Rev*. 2015;96(1):365–408.
38. Sengler C, Zink J, Klotsche J, Niewerth M, Liedmann I, Horneff G, et al. Vitamin D deficiency is associated with higher disease activity and the risk for uveitis in juvenile idiopathic arthritis - Data from a German inception cohort. *Arthritis Res Ther*. 2018;20(1).
39. Sumi SK, Rahman SA, Islam MI, Islam MM TM. Vitamin D Profile in Juvenile Idiopathic Arthritis Patients in a Tertiary Care Hospital in Bangladesh. *Mymensingh Med J*. 2020;29(2):311–6.
40. Nisar MK, Masood F, Cookson P, Sansome A, Östör AJK. What do we know about juvenile idiopathic arthritis and vitamin D? A systematic literature review and meta-analysis of current evidence. Vol. 32, Clinical Rheumatology. 2013. p. 729–34.
41. WHO. Childhood stunting : Context , causes and consequences WHO conceptual framework. *Matern Child Nutr*. 2013;9(September):27–45.
42. Umlawska W, Prusek-Dudkiewicz A. Growth retardation and delayed puberty in children and adolescents with juvenile idiopathic arthritis. *Arch Med Sci*. 2010;6(1):19–23.
43. Filocamo G, Consolaro A, Schiappapietra B, Dalprà S, Lattanzi B, Magni-Manzoni S, et al. A new approach to clinical care of juvenile idiopathic arthritis: The juvenile arthritis multidimensional assessment report. *J Rheumatol*. 2011;38(5):938–53.
44. James Varni. PedsQL Measurement Model [Internet]. 1998 [cited 2020 Dec 17]. Available from: <https://www.pedsq.org/>
45. Tappeiner C, Schneider M, Michels H, Baus H, Zierhut M, Günther A, et al. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. *Semin Arthritis Rheum*. 2018;

46. Mosby. Mosby's Medical Dictionary. 9th ed. Mosby, editor. St. Louis: Elsevier; 2009.
47. Huizinga T, Nigrovic P, Ruderman E, Schulze-Koops H. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Commentary. *Int J Adv Rheumatol*. 2011;9(2):73.
48. Len CA, Miotto E Silva VB, Terreri MTRA. Importance of adherence in the outcome of juvenile idiopathic arthritis. *Curr Rheumatol Rep*. 2014;16(410).
49. Stedman T. Stedman's medical dictionary for the health professions and nursing. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2012.
50. Favier LA, Taylor J, Rich KL, Jones KB, Vora SS, Harris JG, et al. Barriers to adherence in juvenile idiopathic arthritis: A multicenter collaborative experience and preliminary results. *J Rheumatol*. 2018;45(5):690–6.
51. Miller. Encyclopedia & dictionary of medicine, nursing, and allied health. Philadelphia: Saunders; 2003.
52. Dorland. Dorland's Medical Dictionary for Health Consumers. Philadelphia: Saunders; 2007.
53. Ibrahim MB, Labib M, Khozamy H, Badawy WM. Efficacy of physical activities on children with juvenile idiopathic arthritis: a randomized controlled trial. *Bull Fac Phys Ther*. 2020;25(1).
54. Houghton KM. Review for the generalist: Evaluation of anterior knee pain. Vol. 5, *Pediatric Rheumatology*. 2007.
55. Tappeiner C, Klotsche J, Sengler C, Niewerth M, Liedmann I, Walscheid K, et al. Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis. *Arthritis Rheumatol*. 2018;70(10):1685–94.
56. Bechtold S, Simon D. Growth abnormalities in children and adolescents with juvenile idiopathic arthritis. Vol. 34, *Rheumatology International*. 2014. p. 1483–8.
57. Wong SC, Dobie R, Altowati MA, Werther GA, Farquharson C, Ahmed SF. Growth and the growth hormone-insulin like growth factor 1 axis in children with chronic inflammation: Current Evidence, Gaps in Knowledge, and Future Directions. Vol. 37, *Endocrine Reviews*. 2016. p. 62–110.
58. Padeh S, Pinhas-Hamiel O, Zimmermann-Sloutskis D, Berkun Y. Children with oligoarticular juvenile idiopathic arthritis are at considerable risk for growth retardation. *J Pediatr*. 2011;159(5):832–837.e2.
59. Samantha L Huey, Nina Acharya, Ashley Silver, Risha Sheni, Elaine A Yu, Juan Pablo Peña-Rosas SM. Effects of oral vitamin D supplementation on linear growth and other health outcomes among children under five years of age. *Cochrane Database Syst Rev* [Internet]. 2020;8(12). Available from: <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012875.pub2/full>
60. Memari AH, Chamanara E, Ziaee V, Kordi R, Raeeskarami S-R. Behavioral Problems in Juvenile Idiopathic Arthritis: A Controlled Study to Examine the Risk of Psychopathology in a Chronic Pediatric Disorder. *Int J Chronic Dis*. 2016;2016:1–5.
61. El-Najjar AR, Negm MG, El-Sayed WM. The relationship between depression, disease activity and physical function in juvenile idiopathic arthritis patients in Zagazig University Hospitals - Egypt. *Egypt Rheumatol*. 2014;36(3):145–50.
62. Haasnoot AJW, Van Tent-Hoeve M, Wulfraat NM, Schalijs-Delfos NE, Los LI, Armbrust W, et al. Erythrocyte sedimentation rate as baseline predictor for the development of uveitis in children with juvenile idiopathic arthritis. *Am J Ophthalmol*. 2015;159(2):372–377.e1.
63. Gilliam BE, Chauhan AK, Low JM, Moore TL. Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: A comparative study. *Clin Exp Rheumatol*. 2008;26(3):492–7.
64. Pelegrín L, Casaroli-Marano R, Antón J, De Vicuña MCG, Molina-Prat N, Ignacio Aróstegui J, et al. Predictive value of selected biomarkers, polymorphisms, and clinical features for oligoarticular juvenile idiopathic arthritis-associated uveitis. *Ocul Immunol Inflamm*. 2014;
65. Sarkar S, Alam MM, Das G, Datta S. Inflammatory Markers and Disease Activity in Juvenile Idiopathic Arthritis. *Indian J Pediatr*. 2017;84(5):349–56.
66. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. Disease Activity Score 28

- (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients . *Ann Rheum Dis.* 2007;
67. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. *Ann Rheum Dis.* 2007;
 68. Nordal EB, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, et al. Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting. *Ann Rheum Dis.* 2012;
 69. Adriano LS, Fonteles MM de F, Azevedo M de FM, Beserra MPP, Romero NR. Medication adherence in patients with juvenile idiopathic arthritis. *Rev Bras Reumatol.* 2017;57(1):23–9.
 70. De Monte R, Rodger S, Jones F, Broderick S. Living with juvenile idiopathic arthritis: Children’s experiences of participating in home exercise programmes. *Br J Occup Ther.* 2009;72(8):357–65.
 71. Jones F, Rodger S, Broderick S, De Montet R. Living with juvenile idiopathic arthritis: Parents’ experiences of treatment regimens and home exercise programmes. *Br J Occup Ther.* 2009;72(6):249–58.
 72. Hromadkova L, Soukup T, Vlcek J. Quality of life and drug compliance: Their interrelationship in rheumatic patients. *J Eval Clin Pract.* 2015;21(5):919–24.
 73. Kuntze G, Nesbitt C, Whittaker JL, Nettel-Aguirre A, Toomey C, Esau S, et al. Exercise Therapy in Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis. Vol. 99, *Archives of Physical Medicine and Rehabilitation.* 2018. p. 178–193.e1.
 74. McGrady ME, Hommel KA. Medication adherence and health care utilization in pediatric chronic illness: A systematic review. Vol. 132, *Pediatrics.* 2013. p. 730–40.
 75. Medscape. Diclofenac (Rx). 2020.
 76. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 28 Tahun 2019 tentang Angka Kecukupan Gizi yang Dianjurkan untuk Masyarakat Indonesia. Jakarta; 2019.
 77. Kementerian Kesehatan Republik Indonesia. Pedoman Teknis Penilaian Rumah Sehat. 2015.
 78. Russo E, Trevisi E, Zulian F, Battaglia MA, Viel D, Facchin D, et al. Psychological profile in children and adolescents with severe course Juvenile idiopathic arthritis. *Sci World J.* 2012;2012.
 79. K. C, N. J, R. S, N. L, P. M, S.M. B, et al. Patient-Reported Barriers at School for Children with Juvenile Idiopathic Arthritis. *ACR Open Rheumatol [Internet].* 2019;1(3):182–7. Available from: <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L2004364553%0Ahttp://dx.doi.org/10.1002/acr2.1023>
 80. Emerson LM, Bögels S. A Systemic Approach to Pediatric Chronic Health Conditions: Why We Need to Address Parental Stress. Vol. 26, *Journal of Child and Family Studies.* 2017. p. 2347–8.
 81. Cohn LN, Pechlivanoglou P, Lee Y, Mahant S, Orkin J, Marson A, et al. Health Outcomes of Parents of Children with Chronic Illness: A Systematic Review and Meta-Analysis. *J Pediatr.* 2020;218:166–177.e2.
 82. Bradshaw S, Bem D, Shaw K, Taylor B, Chiswell C, Salama M, et al. Improving health, wellbeing and parenting skills in parents of children with special health care needs and medical complexity - A scoping review. *BMC Pediatr.* 2019;19(1).
 83. Hospital MG. Pediatric Symptom Checklist. 2020.
 84. Gardner W, Lucas A, Kolko DJ, Campo J V. Comparison of the PSC-17 and alternative mental health screens in an at-risk primary care sample. *J Am Acad Child Adolesc Psychiatry.* 2007;46(5):611–8.